Howard Schulman, Ph.D. Joins SurroMed, Inc. as Vice President Research and Development
World-renowned biochemist and neurobiologist to
lead biomarker discovery initiative
World-renowned biochemist and neurobiologist to
lead biomarker discovery initiative
Mountain View, Calif. November 29, 2001 SurroMed, Inc. today announced the appointment of Howard Schulman, Ph.D., to the position of vice president of research and development. Dr Schulman is a founding co-director of the Stanford Brain Research Center and former chairman of the Department of Neurobiology, Stanford University School of Medicine. He will direct SurroMed's biomarker discovery initiative focused on enabling the precise diagnosis and effective treatment of disease.
Dr. Schulman, 52, has served as a professor at the Stanford University School of Medicine since 1991, in the Department of Pharmacology and subsequently also in the Department of Neurobiology. He has been a major contributor to progress in the field of molecular pharmacology research for more than 20 years with over 100 peer reviewed articles. Dr. Schulman discovered one of the key protein kinases responsible for transmitting information from calcium-linked hormones, neurotransmitters, and cytokines in heart and brain. The kinase is currently under investigation by several pharmaceutical companies in the CNS and cardiovascular arenas. Dr. Schulman has spent the last year at SurroMed as a visiting scientist while on leave from Stanford Medical School.
"Howard has already made a substantial contribution to SurroMed's biomarker discovery efforts during his sabbatical year from Stanford, and we are thrilled that he has decided to join us," said Gordon Ringold, Ph.D., SurroMed's co-founder, chairman and chief executive officer. "His expertise and depth of knowledge in neurobiology and molecular pharmacology will advance our efforts in biomarker discovery and advance our diagnostic and therapeutic businesses."
Dr. Schulman received his Ph.D. in biological chemistry at Harvard University, studying lipid and carbohydrate metabolism. Subsequently he undertook postdoctoral research focused on pharmacology and signal transduction in the nervous system at Yale University School of Medicine under the supervision of Nobel Laureate Paul Greengard, Ph.D. He joined the Stanford University School of Medicine as an assistant professor and became chairman of the Department of Neurobiology in 1995. He is a member of the editorial board of the Journal of Biological Chemistry, Journal of Neurochemistry, Molecular Neurobiology and Genes to Cells. Dr. Schulman is married with two children.
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic molecules (such as sugars, peptides or lipids) in small volumes of blood and/or other biological samples, while maintaining complete patient confidentiality. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
Contacts:
SurroMed, Inc. Noonan/Russo Communications, Inc.
August J. Moretti Ian McConnell, Ph.D
CFO and General Counsel Senior Account Executive
(650) 230-1564 (415) 677-4455 ext. 233
email: [email protected] email :[email protected]
Dr. Schulman, 52, has served as a professor at the Stanford University School of Medicine since 1991, in the Department of Pharmacology and subsequently also in the Department of Neurobiology. He has been a major contributor to progress in the field of molecular pharmacology research for more than 20 years with over 100 peer reviewed articles. Dr. Schulman discovered one of the key protein kinases responsible for transmitting information from calcium-linked hormones, neurotransmitters, and cytokines in heart and brain. The kinase is currently under investigation by several pharmaceutical companies in the CNS and cardiovascular arenas. Dr. Schulman has spent the last year at SurroMed as a visiting scientist while on leave from Stanford Medical School.
"Howard has already made a substantial contribution to SurroMed's biomarker discovery efforts during his sabbatical year from Stanford, and we are thrilled that he has decided to join us," said Gordon Ringold, Ph.D., SurroMed's co-founder, chairman and chief executive officer. "His expertise and depth of knowledge in neurobiology and molecular pharmacology will advance our efforts in biomarker discovery and advance our diagnostic and therapeutic businesses."
Dr. Schulman received his Ph.D. in biological chemistry at Harvard University, studying lipid and carbohydrate metabolism. Subsequently he undertook postdoctoral research focused on pharmacology and signal transduction in the nervous system at Yale University School of Medicine under the supervision of Nobel Laureate Paul Greengard, Ph.D. He joined the Stanford University School of Medicine as an assistant professor and became chairman of the Department of Neurobiology in 1995. He is a member of the editorial board of the Journal of Biological Chemistry, Journal of Neurochemistry, Molecular Neurobiology and Genes to Cells. Dr. Schulman is married with two children.
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic molecules (such as sugars, peptides or lipids) in small volumes of blood and/or other biological samples, while maintaining complete patient confidentiality. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
Contacts:
SurroMed, Inc. Noonan/Russo Communications, Inc.
August J. Moretti Ian McConnell, Ph.D
CFO and General Counsel Senior Account Executive
(650) 230-1564 (415) 677-4455 ext. 233
email: [email protected] email :[email protected]